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A B S T R A C T
Purpose
To report the results of the Trans Tasman Radiation Oncology Group randomized phase III trial
designed to determine whether the addition of concurrent chemotherapy to postoperative radio-
therapy (CRT) improved locoregional control in patients with high-risk cutaneous squamous cell
carcinoma of the head and neck.
Patients and Methods
The primary objective was to determine whether there was a difference in freedom from locore-
gional relapse (FFLRR) between 60 or 66 Gy (6 to 6.5 weeks) with or without weekly carboplatin
(area under the curve 2) after resection of gross disease. Secondary efﬁcacy objectives were to
compare disease-free survival and overall survival.
Results
Three hundred twenty-one patients were randomly assigned, with 310 patients commencing al-
located treatment (radiotherapy [RT] alone, n = 157; CRT, n = 153). Two hundred thirty-eight patients
(77%) had high-risk nodal disease, 59 (19%) had high-risk primary or in-transit disease, and 13 (4%)
had both. Median follow-up was 60 months. Median RT dose was 60 Gy, with 84% of patients
randomly assigned to CRT completing six cycles of carboplatin. The 2- and 5-year FFLRR rates were
88% (95%CI, 83% to 93%) and 83% (95%CI, 77% to 90%), respectively, for RT and 89% (95%CI,
84% to 94%) and 87% (95% CI, 81% to 93%; hazard ratio, 0.84; 95% CI, 0.46 to 1.55; P = .58),
respectively, for CRT. There were no signiﬁcant differences in disease-free or overall survival.
Locoregional failure was the most common site of ﬁrst treatment failure, with isolated distant
metastases as the ﬁrst site of failure seen in 7% of both arms. Treatment was well tolerated in both
arms, with no observed enhancement of RT toxicity with carboplatin. Grade 3 or 4 late toxicities
were infrequent.
Conclusion
Although surgery and postoperative RT provided excellent FFLRR, there was no observed beneﬁt
with the addition of weekly carboplatin.
J Clin Oncol 36:1275-1283. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Concurrent, platinum-based, postoperative
chemoradiotherapy (CRT) has demonstrated
improvement in locoregional control (LRC),
progression-free survival, and overall survival
(OS) compared with radiotherapy (RT) alone in
patients with high-risk mucosal squamous cell
carcinoma of the head and neck (SCCHN).1,2
Although many have extrapolated the use of
postoperative CRT from these studies to cuta-
neous SCCHN (cSCCHN), particularly in the
presence of positive margins and extracapsular
nodal extension (ECE), there is no high-level
evidence to support its use in this setting.3-5 The
Trans Tasman Radiation Oncology Group (TROG)
conducted a randomized phase III trial, known as
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the POST (Postoperative Skin Trial) study, to determine whether the
addition of concurrent carboplatin to postoperative RT improved
LRC in high-risk cSCCHN (TROG 05.01; ClinicalTrials.gov iden-
tiﬁer: NCT00193895).
PATIENTS AND METHODS
Study Population
Eligibility criteria included the following: histologically proven
cSCCHN, complete macroscopic resection with or without microscopic
positive margins, presence of a high-risk feature of either high-risk nodal
disease and/or advanced primary disease (including in-transit disease)
conﬁned to above the clavicles, Eastern Cooperative Oncology Group
performance status # 2, adequate hematologic function and calculated
creatinine clearance (Cockcroft-Gault) . 40 mL/min, no immuno-
suppression as a result of medication or medical condition, no distant
metastases, no previous radical RT to the head and neck, and no prior
cancers (except those diagnosed . 5 years ago with no evidence of
recurrence).
High-risk nodal disease was deﬁned as intraparotid nodal disease
(any number or size of nodes, with or without ECE, and with or without an
identiﬁable index lesion) and/or cervical nodal disease with a synchronous
index lesion or previously resected primary tumor (, 5 years) within the
corresponding nodal drainage and exclusion of a mucosal primary tumor
with at least computed tomography (CT) scan and/or magnetic resonance
imaging and panendoscopy. For cervical nodal disease to have been eli-
gible, at least one of the following must have been present: two or more
nodes, largest node $ 3 cm, or ECE.
Advanced primary disease was deﬁned, as per the American Joint
Committee on Cancer TNM staging system (sixth edition), as either
being . 5 cm (T3) or invading surrounding cartilage, skeletal muscle, or
bone (T4) of the head and neck and/or in-transit metastases.6 All par-
ticipants provided written informed consent, and the institutional ethics
committees of participating centers approved the protocol.
Study Design
This was a multicenter, open-label, randomized, phase III clinical
trial comparing RTand CRT in patients with high-risk cSCCHN. The trial
was conducted under the auspices of TROG.
Study Treatment
Surgery consisted of resection of the primary lesion, any type of
parotidectomy, and/or any type of neck dissection (ND). Participants with
advanced primary disease without clinical evidence of nodal disease may
have also undergone an elective parotidectomy and/or ND. Patients with
intraparotid nodal disease without a synchronous primary lesion must
have undergone some form of parotidectomy with or without a therapeutic
or elective ND.
Every attempt wasmade to commence RTwithin 6 weeks, but no later
than 9 weeks, after surgery. The trial was initiated before the universal
availability of intensity-modulated RT (IMRT); therefore, patients were
treated with three-dimensional conformal RT. Planning and prescribing
were according to the International Commission on Radiation Units and
Measurements 50 and 62 guidelines.7,8 Initially, RT in both arms consisted
of conventionally fractionated daily treatment to a total of 60 Gy in 30
fractions over 6 weeks to the site of previous gross disease. However,
a modiﬁcation to include the option of 66 Gy in 33 fractions over 6.5 weeks
was included in November 2008 because of concerns by investigators that
60 Gy may have been a suboptimal dose in the presence of microscopic
positive margins. To avoid bias in the treatment arms, investigators were
required to nominate the total RT dose before random assignment. RT
quality assurance (QA) was performed by the TROG QA team. RT var-
iables assessed after therapy included volumes, dosimetry, technique, and
Allocated to CRT
Received allocated CRT
Did not receive allocated CRT
       Experienced progression before
         treatment
       Deemed not suitable for treatment
       Consent withdrawn
(n = 160)
(n = 153)
(n = 7)
(n = 3)
(n = 1)
(n = 3)
Allocation
Analyzed
Excluded from analysis (did not
  receive allocated intervention and no
  further data collected)
(n = 157)
(n = 4)
Analyzed
Excluded from analysis (did not
  receive allocated intervention and no
  further data collected)
(n = 153)
(n = 7)
Analysis
Lost to follow-up
Withdrew consent
(n = 20)
(n = 6)
Lost to follow-up
Withdrew consent
Discontinued intervention
        Adverse event
        Patient choice
(n = 12)
(n = 3)
(n = 23)
(n = 15)
(n = 8)
Follow-Up
Randomly assigned
(N = 321)
Allocated to radiotherapy
Received allocated radiotherapy
Did not receive allocated radiotherapy
       Experienced progression before
         treatment
       Clinician withdrew consent
       Consent withdrawn 
(n = 161)
(n = 157)
(n = 4)
(n = 1)
(n = 1)
(n = 2)
Fig 1. CONSORT diagram. CRT, chemoradiotherapy.
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veriﬁcation with compliance graded as acceptable, minor, major, or
missing/not evaluable.
In the CRT arm, participants were planned to receive weekly car-
boplatin commencing on day 1, 2, or 3 of the RTand repeated on the same
day each week to a maximum of six doses. The drug was administered
intravenously over 20 to 30 minutes before and within 4 hours of receiving
RT. Carboplatin commenced with a dose calculated according to the
Calvert formula to target an area under the curve of 2.0 using a calculated
creatinine clearance.9,10 The calculated dose at baseline was used in all
cycles unless there was a weight change of . 10% from baseline or serum
creatinine changes by . 0.02 mmol/L.
Pretreatment and Follow-Up Evaluations
Pre–random assignment assessment included clinical history,
physical examination, blood tests, CTof head and neck, CTof the chest
or chest x-ray, and health-related quality of life (HRQoL) using
the Functional Assessment of Cancer Therapy–Head and Neck (FACT-
HN) and Functional Assessment of Cancer Therapy–General questionnaires.11,12
During treatment, toxicity was graded weekly according to the Common
Terminology Criteria for Adverse Events (version 3.0), and blood tests
were performed weekly in patients randomly assigned to the CRT arm.
Follow-up assessments were performed at 4, 8, and 12 weeks and then 6,
9, 12, 16, 20, and 24 months after the completion of treatment and every
6 months thereafter up to 5 years or until the close-out date. Toxicity was
classiﬁed as acute or late based on whether it occurred up to or beyond
12 weeks after the completion of treatment.13
HRQoL was assessed at baseline and 12 weeks and then 6, 12, and
24 months after completion of treatment and at recurrence, with the
option of annual assessment until the close-out date or 5 years. Upon
suspicion of suspected recurrence, patients underwent histologic conﬁr-
mation (where feasible), photo documentation, and/or tumor diagram and
restaging CT imaging.
End Points
The primary end point, freedom from locoregional relapse
(FFLRR), was measured from the date of random assignment until the
ﬁrst evidence of locoregional relapse (LRR). If distant relapse oc-
curred, the patient continued to be observed for subsequent LRR.
Therefore, distant relapse was not a censoring event. Death without
preceding LRR was a censoring event for the primary analysis, but
a sensitivity analysis was performed considering death as a competing
event.
LRR was deﬁned as a local (or in-transit) and/or regional relapse. In-
transit relapse was deﬁned as dermal or subcutaneous relapse between the
primary site and the adjoining nodal basin. Disease-free survival (DFS) was
measured from the date of random assignment until ﬁrst relapse at any site
or death from any cause.
OS was measured from the date of random assignment until the date
of death from any cause. For all of the time-to-event end points (FFLRR,
DFS, and OS), patients who did not experience the respective event by the
study close-out date were censored.
The frequency, severity, and relatedness of treatment-related adverse
events (AEs; Common Terminology Criteria for Adverse Events version
3.0) were recorded. The FACT-HN trial outcome index was the primary
HRQoL outcome, scored according to the standard algorithm speciﬁed by
the instrument’s developers.11,12 A change in score of 5% was considered
clinically meaningful.14,15
Random Assignment and Stratification
Participants were randomly assigned in a ratio of 1:1 to RT or CRT.
Stratiﬁed random assignment was used to balance the arms according to
high-risk nodal disease and advanced primary/in-transit disease and in-
stitution. In cases where participants had both risk categories, patients
were stratiﬁed to the high-risk nodal group.
Table 1. Patient, Tumor, and Treatment Characteristics
Characteristic
RT Arm
(n = 157)
CRT Arm
(n = 153)
Median age, years (range) 65 (37-83) 63 (32-85)
Sex
Male 147 (94) 140 (92)
Female 10 (6) 13 (8)
ECOG PS
0 144 (92) 133 (87)
1 12 (8) 20 (13)
2 1 (1) 0 (0)
High-risk feature
High-risk nodal 122 (78) 116 (76)
Advanced primary/in transit 29 (18) 30 (20)
T3 3 1
T4 17 24
In transit 9 4
In transit/T4 0 1
High-risk nodal and advanced primary/
in transit
6 (4) 7 (5)
T3 1 1
T4 4 6
In transit 1 0
High-risk nodal with synchronous
nonadvanced primary
11 (9) 16 (14)
TX 1 3
T1 4 6
T2 6 7
Nodal surgery performed
(elective or therapeutic)
144 (92) 136 (89)
ND only 44 (31) 33 (24)
ND and P 82 (57) 81 (60)
P 18 (12) 22 (16)
P performed
Superﬁcial 64 (64) 71 (69)
Partial 8 (8) 9 (9)
Total 25 (25) 20 (19)
Missing 3 (3) 3 (3)
Nodal pathology status
ND positive 37 (26) 19 (14)
ND and P positive 16 (11) 77 (57)
P positive 68 (47) 24 (18)
ND and/or P negative 23 (16) 16 (12)
Extracapsular extension
Absent 58 (40) 57 (42)
Present 86 (60) 79 (58)
Advanced primary (T3-4) margin
status with or without
high risk nodal disease
25 (16) 33 (22)
Positive 10 16
# 5 mm 7 12
. 5 mm/clear 3 2
Missing 5 3
RT dose*
Median, Gy (range) 60 (60-70) 60 (50-66)
66 Gy 23 (15) 22 (14)
Planned RT delivered 151 (96) 143 (93)
Delayed RT start (. 6 weeks) 17 (11) 19 (12)
Carboplatin (AUC 2)
5 cycles — 12 (8)
6 cycles — 128 (84)
Other — 13 (8)
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: AUC, area under the curve; CRT, chemoradiotherapy; ECOG PS,
Eastern Cooperative Oncology Group performance status; ND, neck dissection;
P, parotidectomy; RT, radiotherapy.
*Five patients received , 60 Gy as a result of discontinuance, whereas three
patients (all in the RT arm) received a dose . 66 Gy as a result of protocol
deviation (68 Gy, n = 1; 70 Gy, n = 2).
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Sample Size
The targeted sample size of 265 patients was determined to detect
a difference of 15% in FFLRR at 2 years (70% and 85% for RT and CRT,
respectively), corresponding to a hazard ratio (HR) of 0.46. It was assumed
that the FFLRR curve for the RT group exhibits an exponential decline to
a plateau at 40% (cure fraction) and that the majority of LRRs occur by
12 months.16,17 With an accrual rate of 45 to 50 patients per year, a further 2
years of follow-up after accrual, a power of 80%, and a signiﬁcance level of
5%, 237 patients were required. To allow for some censored observations, 265
patients were planned for recruitment. After a clinical impression by the Trial
Management Committee (TMC) during the conduct of the study that the
overall LRR rate seemed to be lower than expected, data relevant to the
primary outcome for the RTarm only were extracted in August 2011 for the
purpose of a sample size reassessment. The trial chairs and TMCwere blinded
to this assessment, which was overseen by the Independent Safety and Data
Monitoring Committee. On the basis of these results, an assumed accrual
rate of 45 patients per year, and an unchanged clinically important HR of
0.46, the sample size was recalculated to a total of 350 patients. The
Independent Safety and Data Monitoring Committee recommended the
trial continue with the revised target accrual. The recruitment rate from
2011 onward was noted to be substantially reduced, as a result of factors
such as the introduction of IMRT as standard of care for most head and
neck cancers (HNCs). The TMC elected not to seek an amendment to
include IMRT because it may have affected the secondary outcomes,
complicating the analysis. In 2014, the Independent Safety and Data
Monitoring Committee agreed with the TMC that based on the reduced
accrual rate, the trial was unlikely to meet the revised target and the trial
ceased, with 321 patients being recruited.
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Fig 2. Kaplan-Meier estimates of (A) freedom from locoregional relapse, (B) disease-free survival, and (C) overall survival by treatment arm. CRT, chemoradiotherapy;
RT, radiotherapy.
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Statistical Methods
Time-to-event outcomes (FFLRR, DFS, and OS) were estimated using
the Kaplan-Meier method, with corresponding 95% CIs. The close-out date
was March 30, 2016. Stratiﬁed Cox proportional hazards models were used
to estimate the HR and compare the treatment arms, with the presence of
high-risk nodal disease (yes or no) as a stratiﬁcation variable. A sensitivity
analysis for FFLRR was carried out using competing risks regression with
death as the only competing event.
Patients who withdrew from the trial before treatment who had no
postbaseline data available were excluded from the analysis. All other
patients were analyzed according to treatment arm, regardless of treatment
compliance.
The worst grades of acute and late toxicities were recorded and
described as percentages of the total evaluable patients. Rate of toxicities
were compared between arms using generalized linear models.
HRQoL was analyzed using linear mixed models (LMM) with time
(as factor) included as a ﬁxed effect and patient included as a random
effect. No within-group correlations were assumed, with the model being
ﬁtted by maximizing the restricted log-likelihood. No imputation for
missing values was used. Means and 95% CIs were estimated from the
linear mixed models contrasts.
A post hoc analysis was performed comparing the arms based on the
following subgroups: margin status of resected primary disease, presence of
ECE, number of positive nodes, and size of largest involved node. All
statistical analyses were performed in R version 3.2.3 (www.r-project.org).18
RESULTS
Patient Characteristics
From April 2005 to July 2014, 321 patients from 22 Australian
and New Zealand sites were randomly assigned. CONSORT
ﬂowchart is shown in Figure 1. A total of 11 patients did not receive
the allocated treatment and had no further data collected (RT,
n = 4; CRT, n = 7), leaving 310 evaluable patients (RT, n = 157;
CRT, n = 153). The two arms were balanced with respect to de-
mographic and tumor characteristics (Table 1). The median age
was 65 and 63 years for the RT and CRT arms, respectively. The
majority of patients were men, the predominant Eastern Co-
operative Oncology Group performance status was 0, and the
median follow-up time was 60 months (range, 1.6 to 91.4 months).
Two hundred thirty-eight patients (77%) had high-risk nodal dis-
ease, 59 (19%) had high-risk primary or in-transit disease, and 13
(4%) had both. Superﬁcial parotidectomy was the most common
regional nodal surgery performed. ECE was present in 86% and
79% of patients in the RT and CRT arms, respectively. Of the 251
patients (81%) with high-risk nodal disease, a synchronous pri-
mary tumor (advanced or nonadvanced) or in-transit disease was
present in 16% (Table 1). It was not always possible to obtain
a reliable Tstage for primary lesions when they were metachronous
in patients with advanced nodal disease for various reasons (eg,
lesions treated by a wide range of external centers with T stage not
recorded at initial diagnosis, topical agents used as deﬁnitive
therapy, and/or a history of previous multiple lesions making it
difﬁcult to identify the index lesion). For patients with advanced
primary disease (T3-4) in whom the margin status was known,
a positive margin was seen in 40% (10 of 25 patients) and 48% (16
of 33 patients) of patients in the RT and CRT arms, respectively
(Table 1).
Treatment Compliance
The median RT dose was 60 Gy. The prescribed RT dose was
delivered in 96% and 93% of patients in the RT and CRT arms,
respectively. Commencement of RT was delayed (. 6 weeks) in
11% and 12% of patients in the RT and CRT arms, respectively.
Six doses of chemotherapy were administered to 84% of the
patients in the CRT arm, with 11% requiring a dose reduction
(Table 1).
Efficacy Outcomes
FFLRR, DFS, and OS curves for RT and CRT patients are
shown in Figures 2A, 2B, and 2C, respectively. The 2- and 5-year
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Fig 3. Cumulative incidence of ﬁrst failure in the (A) radiotherapy arm and (B) chemoradiotherapy arm.
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FFLRR rates for RT were 88% (95% CI, 83% to 93%) and 83%
(95% CI, 77% to 90%), respectively, whereas for CRT, they were
89% (95% CI, 84% to 94%) and 87% (95% CI, 81% to 93%; HR,
0.84; 95% CI, 0.46 to 1.55; P = .58), respectively. The results from
the sensitivity analysis with death as a competing event were almost
identical (HR, 0.85; 95% CI, 0.47 to 1.56; P = .60).
The 2- and 5-year DFS rates for RTwere 78% (95%CI, 72% to
85%) and 67% (95% CI, 60% to 76%), respectively, whereas for
CRT, they were 83% (95% CI, 77% to 89%) and 73% (95% CI,
66% to 81%; HR 0.85; 95% CI, 0.55 to 1.29; P = .44), respectively.
The 2- and 5-year OS rates for RTwere 88% (95%CI, 83% to 93%)
and 76% (95% CI, 69% to 84%), respectively, whereas for CRT,
they were 88% (95% CI, 83% to 94%) and 79% (95% CI, 72% to
86%; HR, 0.95; 95% CI, 0.58 to 1.57; P = .86), respectively.
Cumulative incidence of site of ﬁrst failure by arm is shown in
Figure 3. Isolated LRR was the most common site of ﬁrst failure.
Isolated distant failure occurred in 7% of patients in both arms. No
signiﬁcant treatment effect for the primary end point was identiﬁed
in any subgroup (Appendix Fig A1, online only).
AEs
There were no treatment-related deaths. Skin reaction was the
most common AE, whereas the most common chemotherapy-related
Table 2. Acute Treatment-Related Adverse Events (CTCAE V3.0; worse grade) by Arm (from commencement to within 12 weeks of completing treatment)
Adverse Event
No. of Evaluable Patients (%)
RT (n = 156) CRT (n = 152)
Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4
Dermatitis* 80 (51) 76 (49) 94 (62) 58 (38)
Salivary gland 149 (96) 0 141 (93) 0
Otitis externa 109 (70) 1 (1) 92 (61) 1 (1)
Mucositis 131 (84) 16 (10) 118 (78) 16 (11)
Dysphagia 113 (72) 5 (3) 106 (70) 5 (3)
Constipation† 1 (1) 0 32 (21) 1 (1)
Fatigue† 7 (4) 0 40 (26) 1 (1)
Edema 132 (85) 2 (1) 123 (81) 2 (1)
Otitis media 2 (1) 0 2 (1) 0
Dysgeusia† 8 (5) 0 20 (13) 0
Lhermitte 2 (1) 0 2 (1) 0
Chemotherapy related adverse events‡
Hemoglobin 23 (16) 0
Neutrophils 10 (7) 1 (1)
Platelets 26 (18) 1 (1)
Febrile neutropenia 1 (1) 1 (1)
Infection with normal ANC or grade 1 or 2 neutrophils 16 (11) 1 (1)
Infection with unknown ANC 5 (3) 1 (1)
Nausea 81 (55) 3 (2)
Vomiting 22 (15) 1 (1)
NOTE. Two patients did not have acute RT-related adverse events recorded (RT, n = 1; CRT, n = 1).
Abbreviations: ANC, absolute neutrophil count; CRT, chemoradiotherapy; CTCAE, Common Terminology Criteria for Adverse Events; RT, radiotherapy.
*Dermatitis grade 3 or 4: P between arms = .065.
†Presence of toxicity (grade $ 1) between arms was signiﬁcant for constipation (P , .001), fatigue (P , .001), and dysgeusia (P = .018)
‡Chemotherapy-related adverse events were not recorded in ﬁve patients (evaluable, n = 147).
Table 3. Late (# 3 years) Treatment-Related Adverse Events (new or worsening of existing adverse event; CTCAE V3.0)
Toxicity
No. of Evaluable Patients (%)
RT (n = 145) CRT* (n = 149)
Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4
Skin atrophy 51 (35) 0 52 (35) 0
Xerostomia 16 (11) 3 (2) 12 (8) 0
Induration/ﬁbrosis 44 (30) 3 (2) 42 (28) 2 (1)
Telangiectasia 60 (41) 0 78 (52) 0
Trismus 3 (2) 0 1 (1) 0
Osteoradionecrosis 5 (3) 0 4 (3) 1 (1)
Cataract 1 (1) 0 0 0
Ocular surface disease 5 (3) 0 5 (3) 1 (1)
Hearing loss 9 (6) 0 7 (5) 1 (1)
Tinnitus 2 (1) 1 (1) 3 (2) 0
Neuropathy, sensory 3 (2) 0 1 (1) 0
Abbreviations: CRT, chemoradiotherapy; CTCAE, Common Terminology Criteria for Adverse Events; RT, radiotherapy.
*In CRT arm, one patient experienced a grade 3 CNS necrosis.
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AEwas nausea (grade 1 or 2; Table 2). Constipation (P, .001), fatigue
(P, .001), and dysgeusia (P = .018) were more common in the CRT
arm. Excluding skin reaction, grade 3 or 4 AEs were uncommon.
The most common late AEs were telangiectasia, skin atrophy,
and induration or ﬁbrosis. Grade 1 or 2 osteonecrosis was seen in
3% of patients in both arms (Table 3).
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Fig 4. Health-related quality-of-life (HRQoL)
mean scores (95% CIs) by treatment arm from
baseline to 2-year follow-up. (A) Functional As-
sessment of Cancer Therapy–General subscales.
(B) Functional Assessment of Cancer Therapy–
Head and Neck total scores and subscale. CRT,
chemoradiotherapy; RT, radiotherapy; TOI, trial
outcome index.
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RT QA
TROG conducted QA in 301 patients (RT, n = 151; CRT,
n = 150), examining 3,172 variables (Appendix Tables A1 and A2,
online only). Major protocol deviations occurred in 33 patients
(11%), with only 19 deviations (6%) related to dose compliance
within the planning target volumes. The remaining 14 deviations
(5%) were mainly associated with ﬁeld veriﬁcation protocol
compliance.
Quality of Life
HRQoL compliance was low at all visits, 44% at baseline, and
similar on both arms (reasons for noncompliance were not
recorded; Appendix Table A3, online only). The FACT-HN trial
outcome index and all the subscales results were similar between
arms (Fig 4).
DISCUSSION
In this ﬁrst reported randomized phase III trial of CRT in high-risk
cSCCHN, the 2- and 5-year FFLRR rates after surgery and post-
operative RTwere high, and the addition of concurrent carboplatin
did not improve FFLRR, DFS, or OS. On the basis of retrospective
single-institution case series and extrapolation frommucosal HNC
studies, the National Comprehensive Cancer Network guidelines
recommend postoperative RT for positive margins, ECE, two or
more involved nodes, or involved node. 3 cm,3,16,17,19-29 and that
the addition of concurrent chemotherapy should be considered in
the presence of ECE.1,2,4,5
Although this was a negative study, there were a number of
potential limitations that affected the outcome. Consideration
should be given to the following factors: the study was not powered
to detect and cannot exclude a smaller beneﬁt from chemotherapy;
carboplatin was used rather than cisplatin; and despite the best
available evidence at the time, the population did not seem to be as
high risk for locoregional failure as originally anticipated.
At the time of trial design, series reported LRC rates of 40% to
45% with surgery alone depending on extent of nodal disease, with
a 15% to 20% beneﬁt with the addition of postoperative RT.16,20,21
Our initial study design made an assumption of a 2-year FFLRR of
70%with postoperative RTalone. The higher than expected FFLRR
rate in the RT arm of 88% at 2 years now sets the benchmark for
future studies and establishes the control arm in any subsequent
randomized trial testing the addition of other agents in the ad-
juvant setting in immunocompetent patients.
On the basis of the available evidence, we assumed the ad-
dition of concurrent platinum-based chemotherapy would im-
prove 2-year FFLRR by 15%.1,2 At the time of trial design, there
were limited data on the use of systemic therapy for cSCCHN, and
anti–epidermal growth factor receptor agents and immunother-
apies had not entered the clinical domain.30,31 The majority of
studies, but not all, demonstrating superiority of concurrent CRT
inmucosal SCCHN have used cisplatin; however, it was anticipated
that many patients eligible for this study were likely to be elderly
with coexisting medical comorbidities precluding its use.32-34
Hence, we elected to use carboplatin given once weekly during
RT in the experimental arm. Our results do not preclude the
possibility that cisplatin may be efﬁcacious in the postoperative
cSCCHN setting in patients who do not have a contraindication to
cisplatin, but this remains unproven. Although adjuvant treatment
was well tolerated, a higher rate of non–RT-related AEs was seen
in the CRT arm. Severe chemotherapy and late RT toxicity was
uncommon, with no enhancement of late RT toxicity seen with the
addition of carboplatin. There was no apparent difference in
HRQoL; however, results should be interpreted with caution be-
cause of potential nonignorable missing data and low question-
naire completion rates. The importance of RT quality in HNC has
been well documented.35 The low rate of major RT protocol
deviations conﬁrmed the high quality of the treatment delivered,
which may have contributed to the higher than expected FFLRR.
Given the high LRC, interventions that may affect both LRC
and distant metastases would be preferable for future adjuvant
trials. Promising results with immune checkpoint inhibitors in
advanced cSCCHN warrant further evaluation in the adjuvant
setting.31
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Appendix
Trans Tasman Radiation Oncology Group (TROG), Newcastle, New South Wales Australia.
Clinical Trials Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Independent Data and SafetyMonitoring Committee: David Ball and Trevor Leong, PeterMacCallumCancer Centre,Melbourne,
and Martin Stockler, National Health and Medical Research Council (NHRMC) Clinical Trials Centre, New South Wales, Australia.
Val Gebski, NHMRC Clinical Trials Centre, New South Wales, Australia.
Accruing centers: Auckland Hospital, New Zealand (NZ), Calvary Mater Newcastle, New South Wales (NSW), Christchurch
Hospital, NZ, Illawarra Cancer Care Centre, NSW, Andrew Love Cancer Centre, Victoria (VIC), Liverpool Cancer Therapy Centre,
NSW, Mater Queensland Radium Institute, Queensland (QLD), Palmerston North Hospital, NZ, Peter MacCallum Cancer Centre,
VIC, Premion (John Flynn Hospital), QLD, Princess Alexandra Hospital, QLD, Riverina Cancer Centre, NSW, Royal Adelaide
Hospital, South Australia, Royal Brisbane & Women’s Hospital, QLD, Royal North Shore Hospital, NSW, Royal Prince Alfred
Hospital, NSW, St Andrew’s Hospital, QLD, St Vincent’s Hospital, NSW, The Alfred Hospital, VIC, Townsville Cancer Centre, QLD,
Waikato Hospital, NZ, Westmead Hospital, NSW.
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Fig A1. Forest plot of freedom from locoregional relapse comparing chemoradiotherapy (CRT) and radiotherapy (RT) alone in patient subgroups. (*) Primarymargin status
for advanced primary or in-transit and high-risk nodal disease with either synchronous advanced primary (T3-4) or nonadvanced (, T3) primary disease (n = 99). Margin
statuswas unknown ormissing in 16 patients. Clearmarginwas deﬁned as. 5mm. Closemarginwas deﬁned as# 5mmbut not extending to the resection edge. Positive
margin was deﬁned as microscopic extension of disease to resection edge. Nodal size based on the largest diameter of either high risk or low risk nodal disease
Table A1. TROG Quality Assurance Radiotherapy Compliance Report
Category
No. of Patients (%)
Variables Reviewed Acceptable Minor Major Missing/Unevaluable
Schedule 453 444 5 3 1
Dose 906 813 23 19 51
Technique 1,209 1,027 57 1 124
Veriﬁcation 604 591 0 10 3
Total 3,172 2,875 (91) 85 (3) 33 (1) 179 (6)
NOTE. The ﬁrst ﬁve patients from each site were reviewed after treatment. This was followed by a minimum of a one in three random sampling. Parameters reviewed
and variation deﬁnitions are listed in Appendix Table A2.
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Table A2. Radiotherapy Variables and Deﬁnitions
Parameter Acceptable Minor Major
Schedule
Treatment duration, days
PTV3 60 Gy # 44 45-46 . 46
PTV3 66 Gy # 47 48-49 . 49
Total No. of fractions
PTV3 60 Gy 29-31 27-28 or 32 -33 , 27 or . 33
PTV3 66Gy 32-34 30-31 or 35-36 , 30 or . 36
All ﬁelds prescribed for 1 fraction per day Yes — No
Dose
Total dose within PTVl to ICRU reference point, Gy 47.5-52.5 45-47.4 or 52.6-55 , 45 or . 55
Total dose within PTV2 to ICRU reference point, Gy 51.3-56.7 48.6-51.2 or 56.8-59.4 , 48.6 or . 59.4
Total dose within PTV3 to ICRU reference point, Gy
PTV3 60 Gy 57-63 54-56.9 or 63.1-66 , 54 or . 66
PTV3 66 Gy 62.7-69.3 59.5-62.6 or 69.4-72.7 , 59.5 or . 72.7
Minimum dose to PTV3, Gy
PTV3 60 Gy $ 54 51-53.9 , 51
PTV3 66 Gy $ 59.5 56.5-59.4 , 59.4
Maximum dose to PTV3, Gy
PTV3 60 Gy , 67.3 67.3-70.2 . 70.2
PTV3 66 Gy , 74.1 74.1-77.8 . 77.8
Dose per fraction, Gy 1.9-2.1 1.8-1.89 or 2.11-2.2 , 1.8 or . 2.2
Technique
PTVl compliant with protocol Acceptable Marginal Inadequate
PTV2 compliant with protocol Acceptable Marginal Inadequate
PTV3 compliant with protocol Acceptable Marginal Inadequate
CT planning used Yes — Other
Surgical scar marked on plan CT Yes No
Maximum dose to spinal cord, Gy , 47.25 47.5-50 . 50
Maximum dose to brainstem, Gy 54 54.1-56.7 56.8
Maximum dose to optic chiasm, Gy 54 54.1-56.7 56.8
Veriﬁcation
Reference image provided Sim x-ray or DRR — No image provided
Portal images (day 1) taken Yes — No
Portal images (weekly) taken Yes — No
Reference image for electron ﬁelds Yes — No
Abbreviations: CT, computed tomography; DRR, digitally reconstructed radiograph; ICRU, International Commission on Radiation Units; PTV, planning target volume;
PTV1, 50 Gy; PTV2, 54 Gy; PTV3, 60 (66) Gy.
Table A3. Health-Related Quality-of-Life Questionnaire Compliance
Visit
RT CRT
Expected (No.)* Received No. Return Rate (%) Expected (No.)* Received No. Return Rate (%)
Before treatment 157 68 43 153 67 44
12 weeks 154 75 49 150 75 50
6 months 153 76 50 148 76 51
12 months 146 81 55 143 81 57
24 months 128 62 48 124 74 60
Abbreviations: CRT, chemoradiotherapy; RT; radiotherapy.
*Expected numbers represent the number of patients alive, not lost to follow-up, and not having withdrawn consent at the speciﬁc time point.
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